LFNR1 Antibody

What is the functional role of IFNAR1 antibodies in in vivo disease models?

IFNAR1 antibodies block signaling by type I interferons (IFN-α/β), which are central to autoimmune and inflammatory cascades. In lupus-prone BXSB mice, early anti-IFNAR treatment (starting at 8 weeks) reduced glomerular mononuclear cell infiltration by 60%, IgG2a immune complex deposition by 45%, and mortality by 70% compared to controls . In hemorrhagic shock models, IFNAR1 blockade decreased lung myeloperoxidase activity (55% reduction) and serum LDH/AST levels (22–28% reduction), indicating attenuated organ injury . These effects are mediated by inhibiting IFN-α-driven B cell activation and neutrophil recruitment .

Methodological Consideration:

• Model Selection: Use genetically defined murine models (e.g., BXSB for lupus, C57BL/6 for hemorrhagic shock) to isolate IFNAR1-specific effects.

• Treatment Timing: Administer antibodies early in disease progression for maximal efficacy (e.g., at 8 weeks in BXSB mice vs. minimal effect at 20 weeks ).

How do I validate IFNAR1 antibody specificity in Western blotting?

Validation requires a multi-step approach:

• Knockout Controls: Use IFNAR1-KO cell lysates to confirm absence of bands at the expected molecular weight (~110 kDa) .

• siRNA Knockdown: Transiently silence IFNAR1 in wild-type cells and compare band intensity reductions (≥80% recommended) .

• Phosphorylation-Specific Antibodies: For antibodies targeting phosphorylated IFNAR1 (e.g., pSer535/pSer539 ), treat lysates with λ-phosphatase to eliminate signal.

Example Data:

What are the advantages of monoclonal vs. polyclonal IFNAR1 antibodies?

• Monoclonal Antibodies: Ideal for detecting single epitopes (e.g., extracellular domain of IFNAR1). Provide high reproducibility and low batch variability. Recommended for flow cytometry and neutralization assays .

• Polyclonal Antibodies: Detect multiple epitopes, increasing sensitivity for low-abundance targets. Useful in immunohistochemistry (IHC) but require rigorous cross-reactivity checks .

Methodological Tip:
For lupus renal histology, polyclonal antibodies improve detection of diffuse glomerular immune complexes , whereas monoclonal antibodies are preferred for quantifying IFNAR1 surface expression on leukocytes.

How can conflicting data on IFNAR1 antibody efficacy across disease models be resolved?

Discrepancies arise from model-specific genetic backgrounds and disease mechanisms. For example:

• In BXSB mice (TLR7-driven lupus), anti-IFNAR antibodies reduced splenomegaly by 40% .

• In MRL-Fas lpr mice (Fas deficiency-driven lupus), the same treatment showed no survival benefit .

Resolution Strategy:

• Mechanistic Profiling: Compare IFN-α/β levels (ELISA) and downstream ISG expression (RNA-seq) across models.

• Cellular Targeting: Use conditional IFNAR1-KO mice to isolate contributions of immune vs. parenchymal cells.

What protocols optimize IFNAR1 antibody dosing in therapeutic studies?

Titration experiments are critical. For anti-IFNAR antibody (clone MAR1-5A3):

• In Vivo Dose: 1 mg/kg in Ringer’s lactate (effective in hemorrhagic shock ); 10 mg/kg weekly for lupus .

• In Vitro Dose: 5–10 μg/mL for B cell inhibition assays .

Optimization Workflow:

• Test 3–5 doses in pilot studies (e.g., 0.1, 1, 10 mg/kg).

• Measure downstream biomarkers (e.g., CXCL10 for IFNAR1 activity).

• Adjust based on pharmacokinetics (half-life ~72 hours for IgG2a antibodies ).

How do phosphorylation-specific IFNAR1 antibodies (e.g., pSer535/pSer539) enhance signaling studies?

Phospho-specific antibodies enable precise tracking of IFNAR1 activation states. For example:

• Ligand Binding: IFN-β induces stronger Ser535/539 phosphorylation than IFN-α .

• Pathological Correlation: Elevated pSer535 levels correlate with renal inflammation in lupus nephritis .

Experimental Design:

• Stimuli: Treat cells with IFN-α (1000 U/mL) or IFN-β (500 U/mL) for 15–30 minutes.

• Controls: Include unstimulated cells and phosphatase-treated lysates.

What controls are essential when using IFNAR1 antibodies in non-model organisms?

• Sequence Alignment: Verify ≥85% homology between immunogen and target protein (e.g., CLUSTALW analysis ).

• Functional Controls: Confirm antibody blocks IFN-α-induced STAT1 phosphorylation.

Example:
For studying IFNAR1 in non-murine species (e.g., canine lupus):

• Align human IFNAR1 immunogen (UniProt P17181) with canine sequence (85.3% homology).

• Validate using siRNA knockdown in canine PBMCs.